Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
- Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1]
- After a median of 42 months follow-up, the survival rate was 70.2% for women who received Kisqali combination therapy compared to 46.0% for women who received endocrine therapy alone[1]
- Advanced breast cancer in premenopausal women is the leading cause of cancer death in women 20-59 years old[2],[3]
- MONALEESA-7 overall survival results will be presented as a late-breaker at the 2019 ASCO Annual Meeting and will be published in?The New England Journal of Medicine